NCT07923370 Facial Expression Awareness Training to Understand and Recognize Emotions
| NCT ID | NCT07923370 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Children's Hospital of Philadelphia |
| Condition | Survivors of Pediatric Brain Tumors |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-10-30 |
| Primary Completion | 2027-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-10-30 with a primary completion date of 2027-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research is to find out if a computer-based treatment program, called FaceSay, is a feasible and effective intervention for survivors of pediatric brain tumors (SPBT). The goal of this intervention is to improve survivors' facial affect recognition, social attention, and social adjustment.
Eligibility Criteria
Inclusion Criteria: Eligible participants are SPBT who: 1. are between the ages 6-13 2. completed some form of tumor-directed treatment (surgery, chemotherapy, and/or radiation therapy) 3. are off tumor-directed therapy 4. demonstrate difficulties on at least one of the following: 1. Parent- or self-rated Patient-Reported Outcomes Measurement Information System (PROMIS) Peer Relationships Short Form: T-score 1 standard deviation below the mean, which translates to T scores of 40 or below 2. Social Responsiveness Scale-2 (SRS-2): T-score above 60 on any scale 3. Child Behavior Checklist (CBCL): T-score below 30 on social competence scale or T-score above 64 on social problems subscale Exclusion Criteria: Ineligible participants are individuals who: 1. have a genetic condition affecting neurocognitive or social function, or severe developmental delays (excluding NF1, ASD, and Moya Moya) 2. are non-English speaking (FaceSay is only available in English and some assessments only have been validated in English) 4\) a motor or visual limitation that precludes computer use
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07923370 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 13 Years, studying Survivors of Pediatric Brain Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07923370 currently recruiting?
Yes, NCT07923370 is actively recruiting participants. Contact the research team at hockingm@chop.edu for enrollment information.
Where is the NCT07923370 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT07923370 clinical trial?
NCT07923370 is sponsored by Children's Hospital of Philadelphia. The trial plans to enroll 40 participants.